NUFORMIX PLC

Board/Management Information • Dec 1, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1048Y

Nuformix PLC

01 December 2017

Nuformix plc

("Nuformix" or "the Company")

Appointment of Broker

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce the appointment of Beaufort Securities Limited as the Company's broker.

Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX

and www.nuformix.com

ENDS

Enquiries:

Nuformix plc Dan Gooding, Chief Executive Officer	+44 (0)1223 423667
Beaufort Securities Limited (Joint Broker) Jon Belliss	+44 (0)20 7382 8300
Gable Communications Ltd John Bick / Justine James	+44 (0)20 7193 7463

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPFSWSWFFWSEEE